- Home
- GLRE vs CTNM Comparison
GLRE vs CTNM Comparison
Compare GLRE & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | GLRE | CTNM |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.5M | 507.0M |
| IPO Year | 2007 | 2024 |
Fundamental Metrics
Financial Performance| Metric | GLRE | CTNM |
|---|---|---|
| Price | $16.76 | $13.34 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 177.0K | ★ 328.7K |
| Earning Date | 03-09-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.00 | 0.46 |
| EPS | ★ 2.17 | N/A |
| Revenue | ★ $729,777,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.89 | ★ N/A |
| Revenue Growth | ★ 4.85 | N/A |
| 52 Week Low | $11.57 | $3.35 |
| 52 Week High | $17.47 | $16.33 |
Technical Indicators
Market Signals| Indicator | GLRE | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 66.50 | 49.48 |
| Support Level | $12.66 | $10.39 |
| Resistance Level | $17.02 | $15.80 |
| Average True Range (ATR) | 0.56 | 1.09 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 74.83 | 51.85 |
Price Performance
Historical ComparisonAbout GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.